Today: 19 July 2026
Browse Category

NYSE:BMY 10 October 2025 - 15 October 2025

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 15.10.2025

BMY shines under Partha Mohanram’s P/B Growth model with an 88% rating October 15, 2025, 11:18 PM EDT. Validea’s guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock scoring highest under Partha Mohanram’s P/B Growth Investor model, a framework targeting low book-to-market names with signs of sustained growth. BMY, a large-cap growth stock in the Biotechnology & Drugs industry, earns an 88% rating, signaling notable interest from this strategy (scores above 90% show strong interest; around 80% signals some interest). Most tests come back PASS across the framework-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS,
15 October 2025
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle delivery Bms Fiercebiotech. Its lead program, OTX-201, is designed as an in vivo CAR‑T: instead of harvesting and engineering cells outside the body, Orbital will inject circular RNA encoding a CD19-directed CAR into the patient, so the patient’s own T cells become the “manufacturers” of CAR‑T cells in situ Bms Orbitaltx. This approach could greatly simplify CAR‑T therapy logistics. As BMS noted, it may “offer a reduced treatment burden and improved accessibility” relative to conventional ex vivo CAR‑T, which requires cell collection, manufacturing and intensive preparation Bms.
10 October 2025
Go toTop